From: 10th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID)
 | IL-18:CXCL9 ratio at baseline | IFN-γ:CXCL9 ratio at baseline | ||||
---|---|---|---|---|---|---|
Responders | Non-Responders | P value* | Responders | Non-Responders | P value* | |
pACR30 at day 15 | 2.54 (0.03-557.31) | 0.34 (0.01-1.62) | 0.004 | 5.27 (0.19-68.32) | 0.82 (0.24-4.85) | 0.003 |
pACR50Â at day 15 | 2.37 (0.03-557.31) | 0.36 (0.01-3.76) | 0.010 | 5.23 (0.19-68.32) | 1.35 (0.24-5.38) | 0.007 |
pACR70Â at day 15 | 2.54 (0.03-557.31) | 0.57 (0.01-42.27) | 0.052 | 5.27 (0.19-68.32) | 1.56 (0.24-20.03) | 0.015 |
pACR90Â at day 15 | 3.69 (0.03-557.31) | 0.57 (0.01-42.27) | 0.006 | 7.51 (0.19-68.32) | 1.88 (0.19-20.03) | 0.002 |
pACR100Â at day 15 | 3.99 (0.05-557.31) | 0.57 (0.01-42.27) | 0.001 | 8.35 (0.19-68.32) | 1.97 (0.19-43.46) | 0.002 |
CIDÂ at day 15 | 3.84 (0.03-557.31) | 0.66 (0.01-42.81) | 0.015 | 8.34 (0.62-68.32) | 1.97 (0.19-41.52) | 0.002 |
Sustained complete response | 5.52 (0.03-557.31) | 0.65 (0.01-277.69) | 0.002 | 8.35 (0.62-68.32) | 2.01 (0.19-43.46) | 0.002 |